ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 110

Differing Disease Expression In Latin American Mestizo and Spanish Caucasian Patients With Rheumatoid Arthritis With The Same Access To Healthcare and Antirheumatic Treatment

Virginia Ruiz-Esquide1, Sonia Cabrera2, Julio Ramirez3, M. Victoria Hernández2, José Inciarte1, J. D. Cañete3 and Raimon Sanmarti2, 1Arthritis Unit. Rheumatology Service, Hospital Clinic of Barcelona, Barcelona, Spain, 2Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Clinic, Barcelona, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity, ethnic studies and rheumatoid arthritis (RA), Hispanic patients

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) prevalence and clinical phenotype varies between ethnic groups. Few studies have analyzed differences in disease expression between Latin-Americans mestizos (LA) and Caucasians in a population with the same access to healthcare. The purpose of this study is to compare the activity, severity and prognostic factors, of RA in Spanish Caucasians and LA followed at the same Spanish health centre and with the same access to healthcare and antirheumatic therapy.

Methods:
Cross-sectional case-control study of RA patients (ACR 1987 criteria) aged 18-65 years attending a specialized RA clinic of a tertiary Spanish hospital between September 2011 and December 2012. For each LA patient, 2 Spanish Caucasians matched by disease duration (± 12 months) were selected. Sociodemographic variables, disease activity, prognostic markers, serology and treatment were collected and compared between the two groups.

Results:
Of a total of 314 patients with RA, a sample of 153 RA patients (51 LA and 102 Spanish Caucasians) were finally included. The mean age was 47.3 ± 10 years and 88% were female. Disease duration and age at disease onset was similar between groups. LA had  more active disease than Spanish Caucasians as measured by DAS28, number of tender and swollen joints, patient global health assessment or ESR (see table). Remission or low disease activity defined by DAS28 was achieved less frequently by LA patients (15.7% vs. 40.2%, p=0.002, OR 3.61, 95% CI: 1.54 – 8.47 and 31.3% vs. 56.8%, p=0.003, OR 2.88, 95% CI: 1.42- 5.86, respectively). Disability measured by mHAQ and erosive disease were similar in the two groups. There were no significant  differences in the treatment received between groups, although LA patients more frequently received glucocorticoids, synthetic DMARDs and biologic therapy. LA patients more frequently had seropositive RA (rheumatoid factor and/or anti-CCP positive) and were less frequently current and past smokers. Other factors that may be related to disease activity, such as obesity and vitamin D deficiency, were significantly more frequent in LA patients.

Conclusion:
Latin-American mestizo patients had differing prognostic factors and more active RA than Spanish Caucasian patients, despite having the same access to health care and receiving similar antirheumatic therapy.

Table. Disease activity and disability in Caucasian and Latin American  patients with RA.

 

Total

n=153

Caucasian

n=102

Latin American

n=51

p

Age at diagnosis

40.11 ± 11.84

40.54 ± 12.04

39.24 ± 11.51

0.523

Disease duration (months)

91.25 ± 93.03

91.13 ± 92.94

91.5 ± 94.14

0.982

Disease duration < 2 years %

33.98%

22.55%

23.53%

0.892

Age at inclusion

47.30 ± 10.59

47.76 ± 10.73

46.37 ± 10.34

0.554

Sex % (female)

88.2%

87.25%

90.2%

0.595

Obesity (BMI > 25)

57.7%

50%

72.92%

0.009

Smoker

51.4%

63.27%

27.08%

0.000

Anti-CCP+

84.1%

80%

92.57%

0.053

RF +

71.1%

65.35%

82.35%

0.029

TJC

3.42 ± 5.02

2.36 ± 3.38

5.53 ± 6.84

0.003

SJC

2.72 ± 3.91

2.29 ± 3.33

3.57 ± 4.8

0.057

PGH

37.71 ± 19.31

34.41 ± 17.89

44.31 ± 20.52

0.003

DAS28

3.5 ± 1.46

3.16 ± 1.33

4.17 ± 1.49

0.000

Remission DAS28 < 2.6 %

32%

40.2%

15.7%

0.002

Low disease activity DAS28 < 3.2 %

48.4%

56.86%

31.37%

0.003

Pain VAS

34.75 ± 26.97

30.16 ± 21.64

44.74 ± 34.24

0.027

mHAQ

0.374 ± 0.474

0.373 ± 0.45

0.371 ± 0.52

0.986

CRP

0.82 ± 1.22

0.73 ± 1.2

1.01 ± 1.26

0.173

ESR

21.52 ± 19.16

19.44 ± 19.89

25.71 ± 17.01

0.056

Hemoglobin

129.60 ± 12.93

132.04 ± 11.81

124.68 ± 13.65

0.001

Glucocorticosteroids %

52.9%

48.04%

62.75%

0.086

DMARDs %

82.2%

81.2%

86.75%

0.355

Biologic therapy %

38.2%

36.63%

41.18%

0.586

Erosions %

51.9%

51.09%

53.49%

0.795

Vitamin D

19.78 ± 10.75

21.69 ± 10.64

15.88 ± 9.98

0.003

BMI: body mas index, RF: rheumatoid factor, TJC: tender joint count, SJC: swollen joint count, PGH: patient global health asessment, DAS: disease activity index, VAS: visual analogue scale, mHAQ: modified health asnessment quiestionnarie, CRP: C reactive protein, ESR: erythrocyte sedimentation rate, DMARDs: disease-modifying anti-rheumatid drugs.


Disclosure:

V. Ruiz-Esquide,
None;

S. Cabrera,
None;

J. Ramirez,
None;

M. V. Hernández,
None;

J. Inciarte,
None;

J. D. Cañete,
None;

R. Sanmarti,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differing-disease-expression-in-latin-american-mestizo-and-spanish-caucasian-patients-with-rheumatoid-arthritis-with-the-same-access-to-healthcare-and-antirheumatic-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology